0000899243-21-026769.txt : 20210630
0000899243-21-026769.hdr.sgml : 20210630
20210630170514
ACCESSION NUMBER: 0000899243-21-026769
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210628
FILED AS OF DATE: 20210630
DATE AS OF CHANGE: 20210630
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bolzon Bradley J PhD
CENTRAL INDEX KEY: 0001354345
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40522
FILM NUMBER: 211062690
MAIL ADDRESS:
STREET 1: ONE SANSOME STREET
STREET 2: SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Monte Rosa Therapeutics, Inc.
CENTRAL INDEX KEY: 0001826457
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 645 SUMMER STREET
STREET 2: SUITE 102
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 617-949-2643
MAIL ADDRESS:
STREET 1: 645 SUMMER STREET
STREET 2: SUITE 102
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-06-28
0
0001826457
Monte Rosa Therapeutics, Inc.
GLUE
0001354345
Bolzon Bradley J PhD
MONTE ROSA THERAPEUTICS, INC.
645 SUMMER STREET, SUITE 102
BOSTON
MA
02210
1
0
1
0
Common Stock
2021-06-28
4
C
0
6515869
A
6799115
I
By Versant Venture Capital VI, L.P.
Common Stock
2021-06-28
4
C
0
1940043
A
1940043
I
By Versant Vantage I, L.P.
Common Stock
2021-06-28
4
P
0
157895
19.00
A
2097938
I
By Versant Vantage I, L.P.
Series A convertible preferred stock
2021-06-28
4
C
0
20004280
D
Common Stock
5666131
0
I
By Versant Capital VI, L.P.
Series B convertible preferred stock
2021-06-28
4
C
0
3000000
D
Common Stock
849738
0
I
By Versant Capital VI, L.P.
Series B convertible preferred stock
2021-06-28
4
C
0
4150000
D
Common Stock
1175470
0
I
By Versant Vantage I, L.P.
Series C convertible preferred stock
2021-06-28
4
C
0
2699328
D
Common Stock
764573
0
I
By Versant Vantage I, L.P.
Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.
Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
/s/ Ajim Tamboli, Attorney-in-Fact
2021-06-30